Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1278855 | 0.91 | GAA (0.66) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL30712036 | 0.89 | GAA (0.70) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL31103566 | 0.87 | GAA (0.67) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL8072165 | 0.87 | GAA (0.67) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL13586551 | 0.84 | GAA (0.58) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL5012985 | 0.83 | THRA (0.60) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL1525495 | 0.83 | GAA (0.57) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL11156508 | 0.83 | GAA (0.57) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL14666294 | 0.81 | GAA (0.55) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL2560283 | 0.80 | LMNA (0.64) | GAAALDH1A1TSHRNFKB1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012113371-A1 | DETECTION OF DIMERIC CATECHOLAMINE METABOLITES AS INDICATORS OF NEURODEGENERATIVE DISEASES | Thanares GmbH (DE) | 2012-08-30 | — | — | WO | claimed |
| WO-2012113371-A1 | DETECTION OF DIMERIC CATECHOLAMINE METABOLITES AS INDICATORS OF NEURODEGENERATIVE DISEASES | Thanares GmbH (DE) | 2012-08-30 | — | — | WO | disclosed |
| US-20070275944-A1 | Antioxidants and methods of their use | THE BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY | 2007-11-29 | — | — | US | disclosed |
| WO-2007117558-A2 | ANTIOXIDANTS AND METHODS OF THEIR USE | MICHIGAN STATE UNIVERSITY (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20030003497-A1 | Identification of gene sequences and gene products and their specific function and relationship to pathologies in a mammal | MILAGEN, INC. | 2003-01-02 | — | — | US | disclosed |
| US-20020106688-A1 | IDENTIFICATION OF GENE SEQUENCES AND GENE PRODUCTS AND THEIR SPECIFIC FUNCTION AND RELATIONSHIP TO PATHOLOGIES IN A MAMMAL | MILAGEN, INC. | 2002-08-08 | — | — | US | disclosed |
| US-5625081-A | XANTHENE DYE DERIVATIVES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
| US-5608063-A | Method, system and reagents for DNA sequencing | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-03-04 | — | — | US | disclosed |
| US-5558991-A | DNA sequencing method using acyclonucleoside triphosphates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0309969-B1 | Method of gene mapping | DU PONT (US) | 1995-07-19 | — | — | EP | disclosed |
| US-5242796-A | Fluorescent xanthene dye | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0185547-B1 | POLYNUCLEOTIDE HYBRIDIZATION ASSAYS EMPLOYING CATALYZED LUMINESCENCE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-06-03 | — | — | EP | disclosed |
| US-5102785-A | Cleaving to produce DNA fragment which are then end labeled with reporter, again cleaved to produce short fragment, separatiion; analysis | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-04-07 | — | — | US | disclosed |
| EP-0135092-B1 | METHOD FOR DETERMINATION OF AMMONIA | Yamasa Shoyu Kabushiki Kaisha (JP) | 1990-07-25 | — | — | EP | disclosed |
| EP-0309969-A2 | Method of gene mapping | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-05 | — | — | EP | disclosed |
| US-4670379-A | Polynucleotide hydridization assays employing catalyzed luminescence | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-06-02 | — | — | US | disclosed |
| US-4614714-A | Use of novel L-glutamic acid oxidase | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1986-09-30 | — | — | US | disclosed |
| EP-0185547-A2 | Polynucleotide hybridization assays employing catalyzed luminescence | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1986-06-25 | — | — | EP | disclosed |
| EP-0135092-A2 | Method for determination of ammonia | Yamasa Shoyu Kabushiki Kaisha (JP) | 1985-03-27 | — | — | EP | disclosed |
| EP-0097949-A2 | L-glutamic acid oxidase, its production, and its use | Yamasa Shoyu Kabushiki Kaisha (JP) | 1984-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275944-A1 | Antioxidants and methods of their use | GPX1, GPX4, SOD1 | GAA 887/4885ALDH1A1 408/4885TSHR 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.